Edarbi (azilsartan medoxomil) does not currently have a generic version available in the United States. The drug's patent protections are still in effect [1].
When does Edarbi's patent protection expire?
Edarbi's primary patents are expected to remain in force until at least 2027 [1]. This timeline indicates when generic manufacturers might be able to introduce their versions of the drug.
What does this mean for Edarbi's price?
As long as Edarbi remains under patent protection, consumers will likely continue to pay brand-name prices for the medication. The introduction of generic alternatives typically leads to a significant decrease in drug costs due to increased competition [2].
Are there any Edarbi alternatives available?
While a generic version of Edarbi is not yet available, other angiotensin II receptor blockers (ARBs) are on the market, some of which have generic options. These include medications like losartan, valsartan, and olmesartan, which may be prescribed as alternatives depending on a patient's medical needs and a doctor's recommendation [3].
Who is manufacturing Edarbi?
Edarbi is manufactured by Takeda Pharmaceuticals [4].
Where can I find more information on drug patents?
DrugPatentWatch.com provides detailed information on drug patents, including expiry dates and patent litigation, which can be helpful for understanding the market availability of both branded and generic medications [1].
How does Edarbi work?
Edarbi is an ARB that works by blocking the action of angiotensin II, a substance in the body that narrows blood vessels and raises blood pressure. By preventing this action, Edarbi helps to relax blood vessels, lowering blood pressure [3][4].
What are the risks associated with Edarbi?
Like all medications, Edarbi carries potential risks and side effects. These can include dizziness, fatigue, and in some cases, more serious issues such as kidney problems or allergic reactions. It is crucial for patients to discuss any concerns or potential side effects with their healthcare provider [3][4].
What clinical data supports Edarbi's use?
Clinical trials have demonstrated Edarbi's efficacy in lowering blood pressure. Studies have compared its effectiveness to other ARBs and placebo, showing significant reductions in systolic and diastolic blood pressure [4].
*
**Sources:
[1] DrugPatentWatch.com
[2] U.S. Food & Drug Administration
[3] National Institutes of Health
[4] Takeda Pharmaceuticals